EBR Systems
Developer of a leadless left-ventricular endocardial pacing system that uses targeted ultrasound energy to enable synchronized biventricular pacing. The company focuses on device engineering (miniaturized implantable ultrasonic electrodes, subcutaneous transmitters and batteries), clinical development and trials, regulatory submissions and commercialization activities including reimbursement support and clinical training resources.
Industries
Nr. of Employees
medium (51-250)
EBR Systems
Patents
Implantable wireless acoustic stimulators with high energy conversion efficiencies
US-12465777-B2
View DetailsPulse delivery device including slew rate detector, and associated systems and methods
US-12427319-B2
View DetailsImplantable stimulation assemblies having tissue engagement mechanisms, and associated systems and methods
US-12023488-B2
View Details
Implantable wireless acoustic stimulators with high energy conversion efficiencies
US-12465777-B2
View DetailsPulse delivery device including slew rate detector, and associated systems and methods
US-12427319-B2
View DetailsImplantable stimulation assemblies having tissue engagement mechanisms, and associated systems and methods
US-12023488-B2
View DetailsProducts
Leadless left ventricular endocardial pacing system
System composed of a millimeter-scale ultrasonic-sensitive intracardiac electrode, a subcutaneous transmitter and battery module, delivery tools (catheter and sheath) and an external programmer to enable synchronized biventricular pacing without a transvenous LV lead.
Leadless left ventricular endocardial pacing system
System composed of a millimeter-scale ultrasonic-sensitive intracardiac electrode, a subcutaneous transmitter and battery module, delivery tools (catheter and sheath) and an external programmer to enable synchronized biventricular pacing without a transvenous LV lead.
Services
Provision of payer guidance, coding resources, sample claim forms and reimbursement guides for inpatient and outpatient use.
Sponsored presentations, procedural walkthroughs and educational resources for clinicians, including recorded symposiums and presentation slides.
Sponsorship and coordination of prospective post-market observational studies to collect real-world safety and performance data across multiple sites and years.
Provision of payer guidance, coding resources, sample claim forms and reimbursement guides for inpatient and outpatient use.
Sponsored presentations, procedural walkthroughs and educational resources for clinicians, including recorded symposiums and presentation slides.
Sponsorship and coordination of prospective post-market observational studies to collect real-world safety and performance data across multiple sites and years.
Expertise Areas
- Cardiac rhythm management
- Leadless endocardial pacing
- Clinical trial management and post-approval registries
- Medical device engineering and miniaturization
Key Technologies
- Ultrasound-driven implantable pacing
- Implantable ultrasonic transducer electrodes
- Subcutaneous transmitter and battery telemetry
- Catheter-based delivery and intracardiac mapping
News & Updates
Announcement that U.S. Centers for Medicare & Medicaid Services finalized New Technology Add-On Payment (NTAP) and Transitional Pass-Through (TPT) reimbursement effective October 1, 2025, and HCPCS coding for outpatient TPT.
Publication and reporting of interim/pivotal trial results supporting safety and effectiveness of the leadless LV endocardial pacing approach.
Statements on Breakthrough Device interactions, PMA submissions and regulatory approvals for the leadless LV endocardial pacing system (company reporting FDA approval in 2025).
Announcement of appointment of a practicing electrophysiologist as Chief Medical Officer to lead medical and clinical strategy including evidence development, physician education and collaboration with R&D and commercial teams.
Announcement of first patient enrollments in a company-sponsored post-approval registry designed to collect real-world outcomes from commercially treated patients.
Designation granted to the leadless LV endocardial pacing technology during regulatory engagement.
Announcement that U.S. Centers for Medicare & Medicaid Services finalized New Technology Add-On Payment (NTAP) and Transitional Pass-Through (TPT) reimbursement effective October 1, 2025, and HCPCS coding for outpatient TPT.
Publication and reporting of interim/pivotal trial results supporting safety and effectiveness of the leadless LV endocardial pacing approach.
Statements on Breakthrough Device interactions, PMA submissions and regulatory approvals for the leadless LV endocardial pacing system (company reporting FDA approval in 2025).
Announcement of appointment of a practicing electrophysiologist as Chief Medical Officer to lead medical and clinical strategy including evidence development, physician education and collaboration with R&D and commercial teams.
Announcement of first patient enrollments in a company-sponsored post-approval registry designed to collect real-world outcomes from commercially treated patients.
Designation granted to the leadless LV endocardial pacing technology during regulatory engagement.